QSIHealthcare · Medical DevicesThe 3 Wall Street analysts covering Quantum-Si, Inc. hold a median 12-month price target of $2.5 — +235.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Quantum-Si, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (80): Sales and profits are climbing, and climbing faster than before.
Momentum (7): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Quantum-Si, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on QSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +235.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Mar 2026 | Canaccord Genuity | Maintains | Hold | $1.50 → $1.00 |
| 5 Mar 2026 | Canaccord Genuity | Maintains | Hold | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Hold | — |
| 27 Oct 2025 | Canaccord Genuity | Maintains | Hold | — |
| 9 Sept 2025 | Canaccord Genuity | Maintains | Hold | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Feb 2025 | Alliance Global Partners | Initiates | Buy | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2024 | Canaccord Genuity | Maintains | Hold | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Sept 2023 | Canaccord Genuity | Downgrade | Hold | — |
| 20 Oct 2021 | Canaccord Genuity | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 4% of US stocks
Cheaper than 78% of US stocks
Cheaper than 64% of US stocks
Higher than 4% of US stocks
Higher than 34% of US stocks
Higher than 2% of US stocks
Higher than 95% of US stocks
Higher than 22% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QSI appears on the weeks it earns a place.
Quantum-Si announced it will report its second quarter 2026 financial results on August 13, 2026.
Why it matters — This announcement provides a scheduled date for QSI's next financial disclosure, which investors and analysts will watch for updates on the company's performance and progress.
The 3 Wall Street analysts covering Quantum-Si, Inc. have a median 12-month price target of $2.5, with estimates ranging from $1 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Quantum-Si, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quantum-Si, Inc. 32 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Quantum-Si, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (80 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +235.1% from the last close, and Ticker Nerd's factor model ranks Quantum-Si, Inc. 32 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quantum-Si, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $4 over the next 12 months.
Quantum-Si, Inc. returned -48.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Quantum-Si Incorporated is a life sciences company pioneering next-generation protein sequencing (NGPS) through its proprietary single-molecule detection platform. This technology enables researchers to sequence proteins at the single amino acid level, providing unprecedented insights into proteomics for applications such as antibody characterization, biomarker identification, protein variant analysis, and post-translational modification studies.
The most recent item we track (GlobeNewsWire, 27 July 2026): "Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026". Quantum-Si announced it will report its second quarter 2026 financial results on August 13, 2026.
Quantum-Si Incorporated is a life sciences company pioneering next-generation protein sequencing (NGPS) through its proprietary single-molecule detection platform. This technology enables researchers to sequence proteins at the single amino acid level, providing unprecedented insights into proteomics for applications such as antibody characterization, biomarker identification, protein variant analysis, and post-translational modification studies. The company's flagship products include the Platinum and Platinum Pro NGPS instruments, which offer streamlined workflows, automated data analysis, enhanced user interfaces, and options for cloud or on-instrument processing, making advanced protein analysis accessible to labs of all types. Complementary consumables encompass Library Preparation Kits, Barcoding Kits, and Sequencing Kits, along with Platinum Analysis Software for intuitive visualization and workflow automation. By merging semiconductor technology, biology, chemistry, and artificial intelligence, Quantum-Si Incorporated advances the post-genomic era, empowering breakthroughs in drug discovery and diagnostics. Founded in 2013 and headquartered in Branford, Connecticut, it focuses on revolutionizing protein research worldwide.
CEO Mr. Jeffrey Alan Hawkins · 145 employees · United States · https://www.quantum-si.com